BioNTech SE (ADR)
General ticker "BNTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $24.8B (TTM average)
BioNTech SE (ADR) does not follow the US Stock Market performance with the rate: -5.1%.
Estimated limits based on current volatility of 2.9%: low 88.47$, high 93.77$
Factors to consider:
- Total employees count: 1310 as of 2019
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [63.72$, 115.26$]
- 2026-12-31 to 2027-12-31 estimated range: [57.90$, 106.57$]
Financial Metrics affecting the BNTX estimates:
- Negative: with PPE of -22.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Net income
- Positive: -0.02 < Operating cash flow per share per price, % of 2.27
- Positive: Inventory ratio change, % of -18.52 <= -0.75
- Positive: Interest expense per share per price, % of 0.07 <= 0.73
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BNTX quotes
Long-term BNTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €3,819.00MM | €2,751.10MM | €2,756.63MM |
| Operating Expenses | €3,128.60MM | €4,065.40MM | €3,380.50MM |
| Operating Income | €690.40MM | €-1,314.30MM | €-623.87MM |
| Non-Operating Income | €495.70MM | €636.60MM | €-385.46MM |
| Interest Expense | €7.76MM | €13.16MM | €13.64MM |
| R&D Expense | €1,783.10MM | €2,254.20MM | €2,021.83MM |
| Income(Loss) | €1,186.10MM | €-677.70MM | €-1,009.33MM |
| Taxes | €0.00MM | €0.00MM | €81.93MM |
| Net Income(Loss)* | €930.30MM | €-665.30MM | €-1,091.26MM |
| Stockholders Equity | €20,245.90MM | €19,411.10MM | €19,216.02MM |
| Inventory | €357.70MM | €283.30MM | €110.65MM |
| Assets | €23,006.30MM | €22,529.70MM | €21,979.24MM |
| Operating Cash Flow | €5,371.40MM | €207.70MM | €438.00MM |
| Capital expenditure | €705.50MM | €452.30MM | €168.19MM |
| Investing Cash Flow | €-6,954.50MM | €-2,081.20MM | €-2,371.07MM |
| Financing Cash Flow | €-778.60MM | €-45.90MM | €-50.81MM |
| Earnings Per Share** | €3.87 | €-2.77 | €-4.51 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.